Mantle Cell Lymphoma

Reem Karmali, MD, MS, discusses the importance of evaluating older patients with mantle cell lymphoma in the rituximab era.

Reem Karmali, MD, MS, discusses the importance of evaluating older patients with mantle cell lymphoma in the rituximab era.

Michael Wang, MD, discusses the safety and effectiveness of the autologous anti-CD19 CAR T-cell therapy KTE-X19 in patients with higher- versus lower-risk mantle cell lymphoma.

Jia Ruan, MD, PhD, discusses stratifying risk in mantle cell lymphoma.

Reem Karmali, MD, MS, discusses the limitations of intensive therapy in older and medically unfit patients with mantle cell lymphoma (MCL).

China's National Medical Products Administration has approved zanubrutinib (Brukinsa) for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma who have received at least 1 prior therapy, as well as for the treatment of adult patients with mantle cell lymphoma who have received at least 1 prior therapy.

Hun Ju Lee, MD, discusses dosing of the combination of the investigational ROR1 inhibitor cirmtuzumab and ibrutinib in mantle cell lymphoma and chronic lymphocytic leukemia.

Jia Ruan, MD, PhD, discusses the current risk-stratification parameters and the evolution of treatment from high-intensity chemoimmunotherapy to novel therapy in mantle cell lymphoma.

Michael Wang, MD, discusses correlative data from the phase 2 ZUMA-2 trial in mantle cell lymphoma (MCL).

The pharmacodynamic profile of KTE-X19, an autologous anti-CD19 CAR T-cell therapy, was associated with efficacy and treatment-related neurological events among patients with relapsed/refractory mantle cell lymphoma treated within the ZUMA-2 trial.

Preetesh Jain, MD, PhD, discusses the next steps for a study examining the efficacy of venetoclax in high risk relapsed mantle cell lymphoma.

David Miklos, MD, discusses the process of developing KTE-X19 and the ZUMA-2 trial in mantle cell lymphoma.

Preetesh Jain, MD, PhD, discusses response and resistance to venetoclax (Venclexta) in relapsed/refractory mantle cell lymphoma (MCL).

Preetesh Jain, MD, PhD, evaluates mechanisms of resistance to venetoclax in patients with heavily pretreated mantle cell lymphoma and the next phase of this research.

Preetesh Jain, MD, PhD, evaluated mechanisms of resistance to venetoclax in patients with heavily pretreated mantle cell lymphoma and the next phase of this research.

Sonali M. Smith, MD, discusses ongoing research in relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, discusses paradigm shifts in lymphomas and the research efforts driving precision medicine in mantle cell lymphoma.

Michael Wang, MD, discusses research trends in mantle cell lymphoma (MCL).

Andrew D. Zelenetz, MD, PhD, discusses progress made in mantle cell lymphoma treatment.

Andrew D. Zelenetz, MD, PhD, discusses progress made in mantle cell lymphoma treatment.

Michael Wang, MD, discusses the evolution of treatment in mantle cell lymphoma.

Sonali M. Smith, MD, discusses frontline treatment options in mantle cell lymphoma.

Timothy Fenske, MD, MS, discusses the utility of next-generation BTK inhibitors in mantle cell lymphoma.

Diego Villa, MD, MPH, discusses the rationale for a retrospective analysis evaluating bendamustine plus rituximab as induction therapy in patients with mantle cell lymphoma.

Michael Wang, MD, discusses the evolution of treatment in mantle cell lymphoma.